DGAP-News: MagForce AG to attend four upcoming international conferences in September


DGAP-News: MagForce AG / Key word(s): Conference
MagForce AG to attend four upcoming international conferences in September

25.08.2016 / 08:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

MagForce AG to attend four upcoming international conferences in September

Berlin, Germany and Nevada, USA, August 25, 2016 - MagForce AG (Frankfurt,
Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device
company in the field of nanomedicine focused on oncology, announced today
that the Company will participate in four upcoming scientific and investor
conferences in September:

EANS 2016 Congress
Date: September 4-8, 2016
Location: Athens, Greece
Booth: No. 17, level 0
Presentation: Dr. med. Mohammed Jaber, Clinic and Policlinic for
Neurosurgery, University Hospital Münster, "'NanoPaste': Thermotherapy via
nanoparticles directly instilled onto glioma resection cavity walls -
technique and feasibility", Tuesday, 6 September, 2016, 17:00-19:00 EEST

Goldman Sachs European Medtech and Healthcare Services Conference
Date: September 7-8, 2016
Location: London, UK
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 8,
2016; 15:15 BST

36th ESSO Congress
Date: September 14-16, 2016
Location: Krakow, Poland
Booth: No. 3

Berenberg & Goldman Sachs Fifth German Corporate Conference 2016
Date: September 19-21, 2016
Location: Munich, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Wednesday, September 21,
2016; 11:45 CET

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(TM) therapy enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. Mithril Capital
Management, a growth-stage technology fund founded by Ajay Royan and Peter
Thiel, along with MagForce AG, are investors and strategic partners in
MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R)  are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan, and
NanoActivator(R)  are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com  

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list



<pre>

For meeting arrangements or any further questions, please contact us at:

Patient Advocacy

Dr. Katarzyna Zarychta
+49 30 95 477 95-66
k.zarychta@magforce.com

Medical Liaison

Dr. Ulrike Boettcher
+49 89 95 477 95-64
u.boettcher@magforce.com

Media & Investors

Barbara v. Frankenberg
+49 30 30 83 80-77
b.frankenberg@magforce.com


</pre>

Disclaimer 

This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.






Contact:
   
Barbara von Frankenberg
Vice President
Communications & Investor Relations

T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com     


---------------------------------------------------------------------------

25.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

   Language:    English                                             
   Company:     MagForce AG                                         
                Max-Planck-Straße 3                                 
                12489 Berlin                                        
                Germany                                             
   Phone:       +49 (0)30 308 380 0                                 
   Fax:         +49 (0)30 308 380 99                                
   E-mail:      info@magforce.com                                   
   Internet:    www.magforce.com                                    
   ISIN:        DE000A0HGQF5                                        
   WKN:         A0HGQF                                              
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf,  
                Stuttgart, Tradegate Exchange; Open Market (Entry   
                Standard) in Frankfurt                              
 
 
   End of News    DGAP News Service  
---------------------------------------------------------------------------

495619 25.08.2016